Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD.

NCT01670162 is registered in ClinicalTrials.gov with Tennessee Retina as lead sponsor.

NCT NCT01670162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01670162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD.
Lead sponsor
Tennessee Retina
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2012
Completion date
January 31, 2016
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, pigment epithelial detachment